Jiahua He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiahua He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Danrui Bu
College of Veterinary Medicine, Beijing University of Agriculture, No. 7 Beinong Road, Changping, Beijing 102206, China
1 shared publication - Tingting Wan
College of Veterinary Medicine, Beijing University of Agriculture, No. 7 Beinong Road, Changping, Beijing 102206, China
1 shared publication - Xiaoye Liu
Beijing Key Laboratory of Traditional Chinese Veterinary Medicine, Beijing University of Agriculture, No. 7 Beinong Road, Changping, Beijing 102206, China
1 shared publication - Yan Lu
National Experimental Teaching Demonstration Center for Animals, Beijing University of Agriculture, Beijing 102206, China
1 shared publication - Yuting Zhang
College of Veterinary Medicine, Beijing University of Agriculture, No. 7 Beinong Road, Changping, Beijing 102206, China
1 shared publication - Zhao Liu
College of Veterinary Medicine, Beijing University of Agriculture, No. 7 Beinong Road, Changping, Beijing 102206, China
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1538
Genomic Characterization of Multidrug-Resistant Escherichia coli from Bovine Mastitis and Therapeutic Evaluation of Thanatin Combined with Gallium Nitrate
Bovine mastitis caused by multidrug-resistant (MDR) Escherichia coli remains a major challenge in the dairy industry due to recurrent infection, excessive lipopolysaccharide (LPS) release, and persistent mammary inflammation. Whole-genome sequencing (WGS) revealed that the clinical isolate was resistant to seven classes of antibiotics and exhibited a marked enrichment of iron uptake systems, which accounted for 27.14% of the 140 virulence genes identified. Upon this, we developed a targeted combination therapy using the iron mimetic gallium nitrate and the antimicrobial peptide thanatin (Tn). A rat model of mastitis was established to evaluate the in vivo therapeutic efficacy of the Tn-gallium nitrate combination. Our results demonstrated that the combination of gallium nitrate and Tn exerted a potent enhanced therapeutic effect in the rat mastitis model. This regimen significantly inhibited bacterial proliferation, neutralized endotoxin activity, and downregulated the expression of pro-inflammatory cytokines. Histopathological evaluation confirmed that the combination therapy effectively protected the alveolar structure and alleviated tissue damage, with a protective effect superior to that of ceftiofur (CEF), the first-line clinical drug. Collectively, our findings demonstrate the therapeutic potential of the combination of thanatin and gallium nitrate in a rat model of mastitis and provide experimental evidence supporting the development of a novel non-antibiotic therapeutic strategy for bovine mastitis caused by multidrug-resistant E. coli.
- 14 July 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (7) , 1538
Open AccessGenomic Characterization of Multidrug-Resistant Escherichia coli from Bovine Mastitis and Therapeutic Evaluation of Thanatin Combined with Gallium Nitrate
Bovine mastitis caused by multidrug-resistant (MDR) Escherichia coli remains a major challenge in the dairy industry due to recurrent infection, excessive lipopolysaccharide (LPS) release, and persistent mammary inflammation. Whole-genome sequencing (WGS) revealed that the clinical isolate was resistant to seven classes of antibiotics and exhibited a marked enrichment of iron uptake systems, which accounted for 27.14% of the 140 virulence genes identified. Upon this, we developed a targeted combination therapy using the iron mimetic gallium nitrate and the antimicrobial peptide thanatin (Tn). A rat model of mastitis was established to evaluate the in vivo therapeutic efficacy of the Tn-gallium nitrate combination. Our results demonstrated that the combination of gallium nitrate and Tn exerted a potent enhanced therapeutic effect in the rat mastitis model. This regimen significantly inhibited bacterial proliferation, neutralized endotoxin activity, and downregulated the expression of pro-inflammatory cytokines. Histopathological evaluation confirmed that the combination therapy effectively protected the alveolar structure and alleviated tissue damage, with a protective effect superior to that of ceftiofur (CEF), the first-line clinical drug. Collectively, our findings demonstrate the therapeutic potential of the combination of thanatin and gallium nitrate in a rat model of mastitis and provide experimental evidence supporting the development of a novel non-antibiotic therapeutic strategy for bovine mastitis caused by multidrug-resistant E. coli.